Search Results

Chris Cargill appointed as President and Chief Executive Officer • Dr.

success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023 Salipro Biotech

INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris Cargill, President and CEO, will present a company overview at the 41st Annual J.P.

<< Back to podcast list Strategic Partner(s) Chris Langmead Chris Langmead is Professor, Deputy Director Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience

Chris Tate co-founded Heptares after reading one paper on a Friday afternoon. . << Back to podcast list Strategic Partner(s) Chris Tate: Thermostabilizing GPCRs for Structural Biology Chris Tate spent years working on membrane proteins that were simply too unstable to study by crystallography ABOUT THE GUEST Chris Tate is a group leader at the MRC Laboratory of Molecular Biology in Cambridge, Chris Tate obtained his Ph.D. from the University of Bristol in 1989 and then moved to the University

Marshall walks through the decade when membrane proteins kept failing to crystallize in detergent, and how Chris Chris Tate's thermostabilization strategy, which introduced stabilizing mutations selected by thermal Chris Tate and Dr. Richard Henderson at the Laboratory of Molecular Biology in Cambridge, UK.